[HTML][HTML] m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 …
H Zhang, SQ Wang, L Wang, H Lin, JB Zhu… - Cell Death & …, 2022 - nature.com
Gefitinib has been widely applied for the treatment of lung adenocarcinoma (LUAD).
However, the long-term application of gefitinib usually leads to acquired drug resistance in …
However, the long-term application of gefitinib usually leads to acquired drug resistance in …
m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression.
H Zhang, SQ Wang, L Wang, H Lin… - Cell Death & …, 2022 - search.ebscohost.com
Gefitinib has been widely applied for the treatment of lung adenocarcinoma (LUAD).
However, the long-term application of gefitinib usually leads to acquired drug resistance in …
However, the long-term application of gefitinib usually leads to acquired drug resistance in …
m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression
H Zhang, SQ Wang, L Wang, H Lin… - Cell Death and …, 2022 - search.proquest.com
Gefitinib has been widely applied for the treatment of lung adenocarcinoma (LUAD).
However, the long-term application of gefitinib usually leads to acquired drug resistance in …
However, the long-term application of gefitinib usually leads to acquired drug resistance in …
m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression.
H Zhang, SQ Wang, L Wang, H Lin, JB Zhu… - Cell Death & …, 2022 - europepmc.org
Gefitinib has been widely applied for the treatment of lung adenocarcinoma (LUAD).
However, the long-term application of gefitinib usually leads to acquired drug resistance in …
However, the long-term application of gefitinib usually leads to acquired drug resistance in …
[HTML][HTML] m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 …
H Zhang, SQ Wang, L Wang, H Lin, JB Zhu… - Cell Death & …, 2022 - ncbi.nlm.nih.gov
Gefitinib has been widely applied for the treatment of lung adenocarcinoma (LUAD).
However, the long-term application of gefitinib usually leads to acquired drug resistance in …
However, the long-term application of gefitinib usually leads to acquired drug resistance in …
m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression
H Zhang, SQ Wang, L Wang, H Lin… - Cell death & …, 2022 - pubmed.ncbi.nlm.nih.gov
Gefitinib has been widely applied for the treatment of lung adenocarcinoma (LUAD).
However, the long-term application of gefitinib usually leads to acquired drug resistance in …
However, the long-term application of gefitinib usually leads to acquired drug resistance in …